Report

ASH data highlight Coversin’s unique properties

Akari provided an update at the American Society of Hematology (ASH) meeting on the Soliris-resistant patient who has now been well controlled with Coversin for nine months. New data were released supporting a once-daily dosing, with complete inhibition of hemolysis with 22.5mg and 30mg per day. The company also provided guidance on new indications either by leveraging Coversin’s leukotriene B4 activity, or its ease of derivatization into new longer lasting and targeted versions. Results from the Phase II paroxysmal nocturnal hemoglobinuria study are expected in Q117.
Underlying
Akari Therapeutics

Provider
Edison Investment Research
Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

.

Analysts
Maxim Jacobs

Other Reports on these Companies
Other Reports from Edison Investment Research

ResearchPool Subscriptions

Get the most out of your insights

Get in touch